Literature DB >> 11122855

Reducing primary melanoma mortality.

E C Borden1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122855     DOI： 10.1007/s11912-000-0020-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  14 in total

Review 1.  The genetics of hereditary melanoma and nevi. 1998 update.

Authors:  M H Greene
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

Review 2.  Molecular genetics of familial cutaneous melanoma.

Authors:  F G Haluska; F S Hodi
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Germline p16 mutations in familial melanoma.

Authors:  C J Hussussian; J P Struewing; A M Goldstein; P A Higgins; D S Ally; M D Sheahan; W H Clark; M A Tucker; N C Dracopoli
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

4.  Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

Authors:  A C Buzaid; M I Ross; C M Balch; S Soong; W H McCarthy; L Tinoco; P Mansfield; J E Lee; A Bedikian; O Eton; C Plager; N Papadopoulos; S S Legha; R S Benjamin
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group.

Authors:  L Schuchter; D J Schultz; M Synnestvedt; B J Trock; D Guerry; D E Elder; R Elenitsas; W H Clark; A C Halpern
Journal:  Ann Intern Med       Date:  1996-09-01       Impact factor: 25.391

Review 6.  Biochemotherapy for melanoma.

Authors:  P A Philip; L E Flaherty
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

7.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

8.  Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

Authors:  C Garbe; P Büttner; J Bertz; G Burg; B d'Hoedt; H Drepper; I Guggenmoos-Holzmann; W Lechner; A Lippold; C E Orfanos
Journal:  Cancer       Date:  1995-05-15       Impact factor: 6.860

Review 9.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Authors:  L M Pfeffer; C A Dinarello; R B Herberman; B R Williams; E C Borden; R Bordens; M R Walter; T L Nagabhushan; P P Trotta; S Pestka
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

Review 10.  Vaccination for melanoma.

Authors:  L W Thompson; L Brinckerhoff; C L Slingluff
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.945
View more
  1 in total

1.  Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.

Authors:  Keke Fan; Ernest Borden; Taolin Yi
Journal:  J Interferon Cytokine Res       Date:  2009-08       Impact factor: 2.607
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.